Loading…
Operates in Pharma — Distribution. Per the activity note to the FY2024 annual report, the company trades in pharmaceutical products. Prepares financial statements under SME financial reporting standards.
| Ratio | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Margins | ||||||
| Gross Margin | 143.2% | 60.1% | 52.7% | 57.3% | 30.1% | 68.2% |
| EBITDA Margin | 144.4% | 61.4% | 50.2% | 55.8% | 33.9% | 68.3% |
| EBITDAR | 10,878 | 6,385 | 5,446 | 8,232 | 1,774 | 3,739 |
| EBITDAR Margin | 144.4% | 61.4% | 50.2% | 55.8% | 34.1% | 68.3% |
| EBIT Margin | 144.4% | 61.4% | 50.2% | 55.8% | 33.9% | 68.3% |
| Net Profit Margin | 101.2% | 61.4% | 50.2% | 55.8% | 31.2% | 68.2% |
| Operating Expense % of Sales | 1.2% | 1.3% | 2.6% | 1.5% | 3.8% | 0.1% |
| Returns | ||||||
| Return on Assets (ROA) | 117.0% | 142.6% | 107.0% | 155.9% | 75.7% | 143.3% |
| Return on Equity (ROE) | 175.2% | 233.8% | 217.1% | 586.1% | N/A | N/A |
| ROIC [EBIT / Invested Capital] | 200.6% | 158.5% | 155.6% | 366.9% | N/A | N/A |
| Leverage & debt balances | ||||||
| Debt-to-Assets | 20.7% | 30.1% | 28.2% | 27.2% | 66.9% | 55.0% |
| Debt-to-Equity | 0.31x | 0.49x | 0.57x | 1.02x | -0.54x | -1.37x |
| Debt-to-EBITDA | 0.12x | 0.21x | 0.26x | 0.17x | 0.81x | 0.38x |
| Equity-to-Assets | 66.8% | 61.0% | 49.3% | 26.6% | -123.2% | -40.0% |
| Net Debt | 1,073 | 1,299 | 992 | 839 | 1,212 | 884 |
| Cash & Equivalents | 278 | 52 | 442 | 595 | 222 | 550 |
| Total Debt | 1,350 | 1,350 | 1,434 | 1,434 | 1,434 | 1,434 |
| Liquidity & working capital | ||||||
| Current Ratio | 7.99x | 11.26x | 4.13x | 2.09x | 0.62x | 1.13x |
| Quick Ratio | 7.99x | 7.41x | 1.67x | 0.39x | 0.62x | 1.13x |
| Cash Ratio | 0.34x | 0.13x | 0.36x | 0.24x | 0.06x | 0.24x |
| Total Current Assets | 6,516 | 4,479 | 5,091 | 5,282 | 2,145 | 2,610 |
| Total Current Liabilities | 816 | 398 | 1,233 | 2,527 | 3,437 | 2,303 |
| Inventory | N/A | 1,531 | 3,027 | 4,298 | N/A | N/A |
| Trade Receivables | 4,609 | 2,896 | 1,619 | 388 | 7 | 1,857 |
| Trade Payables | 814 | 397 | 1,148 | 2,443 | 2,332 | 2,219 |
| Net Working Capital | 5,700 | 4,081 | 3,858 | 2,755 | -1,292 | 306 |
| Net Working Capital % of Revenue | 75.7% | 39.3% | 35.6% | 18.7% | -24.8% | 5.6% |
| Trade Working Capital | 3,795 | 4,030 | 3,498 | 2,243 | -2,325 | -363 |
| Trade Working Capital % of Revenue | 50.4% | 38.8% | 32.2% | 15.2% | -44.6% | -6.6% |
| Change in Trade Working Capital | N/A | 236 | -533 | -1,255 | -4,568 | 1,963 |
| Turnover & efficiency | ||||||
| Inventory Turnover | N/A | 2.71x | 1.69x | 1.46x | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | 134.8 | 215.4 | 249.5 | N/A | N/A |
| Receivables Turnover | 1.63x | 3.59x | 6.70x | 37.99x | 730.23x | 2.95x |
| Days Sales Outstanding (DSO) | 223.4 | 101.7 | 54.4 | 9.6 | 0.5 | 123.7 |
| Payables Turnover | 4.00x | 10.45x | 4.47x | 2.57x | 1.56x | 0.79x |
| Days Payable Outstanding (DPO) | 91.2 | 34.9 | 81.7 | 141.8 | 233.8 | 464.6 |
| Cash Conversion Cycle | 132.1 days | 201.5 days | 188.2 days | 117.3 days | -233.3 days | -340.9 days |
| Asset Turnover | 1.16x | 2.32x | 2.13x | 2.79x | 2.43x | 2.10x |
| Cash flow & dividends | ||||||
| Operating Cash Flow | -72 | -226 | 48 | 153 | -629 | 311 |
| Free Cash Flow (OCF − Capex proxy) | -72 | -226 | 390 | 153 | -629 | 311 |
| Cash Conversion (OCF / EBITDA) | -0.7% | -3.5% | 0.9% | 1.9% | -35.7% | 8.3% |
| Dividends Declared | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in GEL, thousands. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →